Skandinaviska Enskilda Banken Ab (Publ) Ligand Pharmaceuticals Inc Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$58.86 - $72.67 $82,404 - $101,738	1,400 Added 8.43%	18,000 $1.08 Million
Q2 2023 Aug 07, 2023	SELL	$69.53 - $79.33 $417,180 - $475,980	-6,000 Reduced 26.55%	16,600 $1.2 Million
Q1 2023 May 11, 2023	BUY	$65.67 - $77.08 $1.48 Million - $1.74 Million	22,600 New	22,600 $1.66 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.1B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.